CG
AMAG

Clinton Group’s AMAG Pharmaceuticals AMAG Stock Holding History

Clinton Group’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-15,090
Closed -$353K – 1094
2016
Q1 		$353K Buy
+15,090
New +$358K 0.02% 701
2015
Q3 		– Sell
-4,205
Closed -$290K – 880
2015
Q2 		$290K Buy
+4,205
New +$265K 0.04% 482

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Clinton Group's AMAG Position: Q2 2016 in Review

Clinton Group sold out of AMAG Pharmaceuticals (AMAG) in Q2 2016, closing a stake of 15,090 shares — an estimated $353K sold.

Clinton Group first reported a position in AMAG in Q2 2015 and held it in 2 quarters. The position peaked at $353K in Q1 2016. 165 funds tracked by Wall St. Rank hold AMAG as of Q2 2016.

  • Clinton Group reported no remaining AMAG Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Clinton Group sold 15,090 AMAG Pharmaceuticals shares in Q2 2016, an estimated $353K.
  • Clinton Group first reported a position in AMAG Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Clinton Group's AMAG Pharmaceuticals position peaked at $353K in Q1 2016.
  • 165 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2016.

Based on Clinton Group's 13F filing for Q2 2016, filed 12 Aug 2016.